EPH27 Association Between Prescribing Specialty and Treatment-Related Complications in Patients Using Novel Hormonal Agents for Metastatic Castration-Resistant Prostate Cancer: Population-Based Study

Novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and enzalutamide (ENZ) are frequently used in metastatic castration-resistant prostate cancer (mCRPC). While mCRPC treatment has been traditionally administered by medical oncologists, urologists have also adopted the use of NHAs. The objective was to assess the association between the incidence of NHA-related complications and prescribing specialty in mCRPC patients treated with NHAs.